Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of N-acetylcysteine in Moderate COVID-19
NCT04792021Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetylcysteine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ain Shams University. Primary endpoint: Tumor Necrosis Factor alpha level at 2 weeks. Started Mar 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04792021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792021.